We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Maternal HbA1c Influences Autism Risk in Offspring

By LabMedica International staff writers
Posted on 04 Jul 2019
Print article
Image: An increase in HBA1c levels in pregnancy is associated with an increased risk for autism in the child (Photo courtesy of Thai Anti-Diabetes).
Image: An increase in HBA1c levels in pregnancy is associated with an increased risk for autism in the child (Photo courtesy of Thai Anti-Diabetes).
Epidemiologic data suggest that maternal diabetes influences the risk for autism in offspring, whereas the prevalence of autism has steadily risen in the USA, currently affecting 1 in 59 children, and boys are four to five times more likely to receive an autism diagnosis.

According to a comprehensive survey children born to women with glycated hemoglobin (HbA1c) level of at least 6.5% were nearly twice as likely to receive a diagnosis of autism in the first four years of life versus offspring of mothers with HbA1c below 5.7%.

Scientists carried out a retrospective study and analyzed electronic medical records data from 35,819 mother-infant pairs (51% boys) born in hospitals connected to Kaiser Permanente Southern California (Pasadena, CA, USA) from 2012 to 2013 (maternal mean maternal age, 31 years; mean pre-pregnancy BMI, 27.2 kg/m²; 51% Hispanic). The team followed the children until they received a diagnosis of autism with at least one diagnostic code or December 31, 2017. The last maternal HbA1c level in the first two trimesters of pregnancy was obtained from the electronic laboratory database. HbA1c was analyzed as a continuous variable and a categorical variable, classified as less than 5.7%, 5.7% to 5.9%, 6% to 6.5%, and greater than 6.5%.

Within the cohort, 84.9% of mothers had an HbA1c less than 5.7%; 11.7% had an HbA1c between 5.7% and 5.9; 2.4% between 6% and 6.5%; and 1% greater than 6.5%. During a median follow-up of 4.5 years, 707 children (2%) had a clinical diagnosis of autism. After adjusting for pre-pregnancy BMI and race, the Hazard Ratio (HR) for autism associated with each 1% increase of HbA1c level was 1.12 (95% CI, 0.96-1.31) for the continuous measure. Compared with children with a maternal HbA1c of less than 5.7%, children born to women with an HbA1c greater than 6.5% were nearly twice as likely to receive a diagnosis of autism during follow-up (HR = 1.79; 95% CI, 1.06-3).

Anny H. Xiang, PhD, director of biostatistics for Kaiser Permanente Southern California, said, “Maternal diabetes, if not well treated, which means hyperglycemia in utero, that increases uterine inflammation, oxidative stress and hypoxia and may alter gene expression. This can disrupt fetal brain development, increasing the risk for neural behavior disorders, such as autism.” The study was presented at the American Diabetes Association 79th Scientific Meeting held June 7-11, 2019, in San Francisco, CA, USA.

Related Links:
Kaiser Permanente Southern California

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test

Print article

Channels

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.